GAIN THERAPEUTICS

gain-therapeutics-logo

Gain Therapeutics is a developer of pharmacological chaperones drugs designed to treat rare metabolic disorders. The company's drugs utilize Minoryx Direct Enzyme Therapy to identify a new generation of uncomplicated adjuvants, enabling clients to help patients stabilize misfolding mutations and restore protein's enzymatic activity. It targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Established in 2017 and is headquartered in Bethesda, MD, USA.

#SimilarOrganizations #People #Financial #Event #Website #More

GAIN THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical Therapeutics

Founded:
2017-01-01

Address:
Bethesda, Maryland, United States

Country:
United States

Website Url:
http://www.gaintherapeutics.com

Total Employee:
11+

Status:
Active

Contact:
301-500-1556

Email Addresses:
[email protected]

Total Funding:
14.4 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.


Current Advisors List

joanne-taylor_image

Joanne Taylor Scientific Advisor @ Gain Therapeutics
Advisor
2020-09-01

Current Employees Featured

eric-richman_image

Eric Richman
Eric Richman Chief Executive Officer @ Gain Therapeutics
Chief Executive Officer
2020-07-01

lorenzo-leoni_image

Lorenzo Leoni
Lorenzo Leoni Vice Chairman and Founder @ Gain Therapeutics
Vice Chairman and Founder

khalid-islam_image

Khalid Islam
Khalid Islam Co-Founder and Chairman @ Gain Therapeutics
Co-Founder and Chairman

matthias-alder_image

Matthias Alder
Matthias Alder Chief Operating Officer @ Gain Therapeutics
Chief Operating Officer
2021-10-01

roberto-maj_image

Roberto Maj
Roberto Maj Head of Development @ Gain Therapeutics
Head of Development
2019-03-01

xavier-barril_image

Xavier Barril
Xavier Barril CSO @ Gain Therapeutics
CSO
2018-01-01

Founder


khalid-islam_image

Khalid Islam

lorenzo-leoni_image

Lorenzo Leoni

Stock Details


Company's stock symbol is NASDAQ:GANX

Investors List

horizon-2020_image

Horizon 2020

Horizon 2020 investment in Grant - Gain Therapeutics

eurostars_image

Eurostars

Eurostars investment in Grant - Gain Therapeutics

innosuisse_image

InnoSuisse

InnoSuisse investment in Grant - Gain Therapeutics

vitatech-s-a_image

VitaTech S.A

VitaTech S.A investment in Series A - Gain Therapeutics

helsinn-investment-fund_image

3B Future Health Fund

3B Future Health Fund investment in Series A - Gain Therapeutics

tiventure_image

TiVentures

TiVentures investment in Series A - Gain Therapeutics

Key Employee Changes

Date New article
2021-10-19 Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

Official Site Inspections

http://www.gaintherapeutics.com Semrush global rank: 3.75 M Semrush visits lastest month: 3.6 K

  • Host name: 104.16.150.108
  • IP address: 104.16.150.108
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Gain Therapeutics"

About Us: Our Mission & Values | Gain Therapeutics

Dr. Terenzio Ignoni, joined Gain Therapeutic in June 2021 as SVP Quality and CMC bringing with him more than 22 years of hands-on experience in pharmaceutical technical operations, …See details»

Gain Therapeutics - Crunchbase Company Profile

Gain Therapeutics is a developer of pharmacological chaperones drugs designed to treat rare metabolic disorders. The company's drugs utilize Minoryx Direct …See details»

Gain Therapeutics - LinkedIn

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders And Provides Operational Update "We hope 2025 is a year of immense progress – not only for Gain but the field as a whole – and ...See details»

Gain Therapeutics - businessabc.net

Feb 25, 2025 Gain Therapeutics was founded in 2020 by a team of renowned scientists, physicians and entrepreneurs with a vision to redefine the landscape of therapeutic development.See details»

Gain Therapeutics | Investor Info, News & Corporate Updates

Mar 17, 2025 Stay updated on Gain Therapeutics’ stock info, events, press releases, and corporate updates. Explore key investor resources and company developments.See details»

Gain Therapeutics - Overview, News & Similar companies

May 22, 2024 Gain Therapeutics contact info: Phone number: (301) 500-1556 Website: www.gaintherapeutics.com What does Gain Therapeutics do? Gain Therapeutics, Inc. is …See details»

Gain Therapeutics - Craft

Oct 29, 2024 Gain Therapeutics has 3 employees across 3 locations and $55.18 k in annual revenue in FY 2023. See insights on Gain Therapeutics including office locations, competitors, …See details»

Gain Therapeutics Company Overview, Contact Details

Nov 24, 2023 Gain Therapeutics, Inc. hired Gene Mack as interim CEO on Jan 6th '25. BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) - Gain Therapeutics, Inc. (Nasdaq: …See details»

Behind the scenes of Gain Therapeutics COO: Matthias Alder

I want to positively influence the organization and work with my colleagues to achieve the company mission, which is to accelerate drug discovery and development with our platform …See details»

GT Gain Therapeutics SA – Swiss Biotech

A clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is …See details»

Gain Therapeutics, Inc. (Gain Therapeutics, Inc.) - 药物管线_专利_ …

Investor Contacts:Apaar Jammu and Chuck [email protected]@lifesciadvisors.com Media Contacts:Russo …See details»

News & Events | Gain Therapeutics Investor Relations

Mar 14, 2025 Get the latest updates, events, and announcements from Gain Therapeutics. Stay informed on key developments and corporate milestones for investors and stakeholders.See details»

Gain Therapeutics | LinkedIn

Gain Therapeutics | 4.558 Follower:innen auf LinkedIn. Unfolding the next generation of allosteric small molecule therapies to meet patient needs | Gain Therapeutics, Inc. is a clinical-stage …See details»

Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI …

Gain Therapeutics Revolutionary Drug Discovery: Combining Physics, Biochemistry, and Supercomputing; Oppenheimer Virtual Fireside Chat: Targeting the Undruggable – Latest …See details»

Gain Therapeutics’ collaboration with Zentalis Pharmaceuticals so ...

On April 20th, 2021, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets.See details»

Gain Therapeutics Reports Financial Results for the Fourth Quarter …

9 hours ago Cash, cash equivalent and marketable securities were $10.4 million as of December 31, 2024, compared to $16.8 million as of December 31, 2023.. About GT-02287 Gain …See details»

Gain Therapeutics Reports Financial Results for the Fourth Quarter …

First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025. BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: …See details»

Gain Therapeutics Reports Financial Results for the Fourth

10 hours ago Gain Therapeutics, Inc Consolidated Statements of Operations Year Ended December 31, 2024 2023 Revenues: Collaboration revenuesSee details»

Gain Therapeutics Revolutionary Drug Discovery

Discovering treatments for patients that currently have no available disease-modifying options is the priority of Gain Therapeutics. Specifically, there is a large unmet need for patients suffering …See details»

Gain Therapeutics Reports Financial Results for the Fourth Quarter …

9 hours ago First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. …See details»

linkstock.net © 2022. All rights reserved